524470 Stock Overview Manufactures, markets, and sells pharmaceutical formulation products in India. More details
Rewards Risk Analysis No risks detected for 524470 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Syncom Formulations (India) Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Syncom Formulations (India) Historical stock prices Current Share Price ₹19.86 52 Week High ₹27.94 52 Week Low ₹11.00 Beta 1.62 1 Month Change -2.07% 3 Month Change -9.65% 1 Year Change 32.05% 3 Year Change 50.91% 5 Year Change 2,513.16% Change since IPO 1,221.48%
Recent News & Updates
Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024) Nov 12
Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024 Nov 05
Investor sentiment deteriorates as stock falls 15% Sep 19
Investor sentiment improves as stock rises 22% Aug 21
Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024 Aug 13
First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024) Aug 13 See more updates
Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024) Nov 12
Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024 Nov 05
Investor sentiment deteriorates as stock falls 15% Sep 19
Investor sentiment improves as stock rises 22% Aug 21
Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024 Aug 13
First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024) Aug 13
Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024 Aug 02
Investor sentiment improves as stock rises 17% Jul 15
Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023) May 19
Investor sentiment improves as stock rises 17% Apr 03
Syncom Formulations (India) Limited Announces Board Changes Mar 29
Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023) Feb 15
Investor sentiment improves as stock rises 20% Dec 26
Investor sentiment improves as stock rises 25% Nov 23
Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023) Nov 11
Investor sentiment improves as stock rises 23% Nov 09 Syncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024
Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023 Aug 15
First quarter 2024 earnings released Aug 15
Investor sentiment improves as stock rises 18% Aug 07
Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023 Aug 04
Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022) Jun 02
Investor sentiment deteriorates as stock falls 18% Mar 28
Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022) Feb 14
Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023 Feb 02
Investor sentiment improved over the past week Dec 23
Second quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.06 in 2Q 2022) Nov 19
Insufficient new directors Nov 16
Syncom Formulations (India) Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022 Sep 20
Upcoming dividend of ₹0.03 per share Sep 02
First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.08 in 1Q 2022) Aug 18
Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022 Aug 16
Investor sentiment improved over the past week Jul 21
Syncom Formulations (India) Limited Appoints Ruchi Jindal as an Additional Director Jun 29
Now 25% undervalued after recent price drop Jun 20
Investor sentiment deteriorated over the past week Jun 16
Full year 2022 earnings released: EPS: ₹0.26 (vs ₹0.38 in FY 2021) May 24
Investor sentiment deteriorated over the past week May 10
Insufficient new directors Apr 27
Investor sentiment improved over the past week Apr 07
Investor sentiment improved over the past week Mar 14
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 17
Investor sentiment deteriorated over the past week Feb 17
Investor sentiment improved over the past week Dec 29
Investor sentiment improved over the past week Oct 07
Investor sentiment improved over the past week Sep 22
Investor sentiment deteriorated over the past week Aug 20
Investor sentiment deteriorated over the past week Jul 29
Full year 2021 earnings released: EPS ₹0.38 (vs ₹0.17 in FY 2020) Jul 04
Investor sentiment improved over the past week Apr 14
New 90-day low: ₹3.09 Mar 14
Third quarter 2021 earnings released: EPS ₹0.13 (vs ₹0.04 in 3Q 2020) Feb 17
Syncom Formulations (India) Limited to Report Q3, 2021 Results on Feb 12, 2021 Feb 04
New 90-day high: ₹3.72 Jan 06
Syncom Formulations (India) Limited announced that it expects to receive INR 100.787496 million in funding Dec 20
Market bids up stock over the past week Dec 02
New 90-day high: ₹1.93 Nov 17
Market bids up stock over the past week Nov 13
New 90-day low: ₹1.42 Oct 15
First quarter earnings released Aug 20
Syncom Formulations (India) Limited to Report Q4, 2020 Results on Jun 30, 2020 Jul 05 Shareholder Returns 524470 IN Pharmaceuticals IN Market 7D -2.7% 1.7% 0.2% 1Y 32.0% 39.1% 17.2%
See full shareholder returns
Return vs Market: 524470 exceeded the Indian Market which returned 17.2% over the past year.
Price Volatility Is 524470's price volatile compared to industry and market? 524470 volatility 524470 Average Weekly Movement 6.9% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 524470 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524470's weekly volatility (7%) has been stable over the past year.
About the Company Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations.
Show more Syncom Formulations (India) Limited Fundamentals Summary How do Syncom Formulations (India)'s earnings and revenue compare to its market cap? 524470 fundamental statistics Market cap ₹18.67b Earnings (TTM ) ₹331.45m Revenue (TTM ) ₹3.28b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 524470 income statement (TTM ) Revenue ₹3.28b Cost of Revenue ₹2.04b Gross Profit ₹1.25b Other Expenses ₹915.54m Earnings ₹331.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.35 Gross Margin 37.98% Net Profit Margin 10.10% Debt/Equity Ratio 4.5%
How did 524470 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/28 21:55 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Syncom Formulations (India) Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
